Last reviewed · How we verify

hMG subcutaneous injection

Granata Bio Corporation · Phase 3 active Small molecule

hMG subcutaneous injection is a Growth hormone Small molecule drug developed by Granata Bio Corporation. It is currently in Phase 3 development for Growth hormone deficiency in children.

hMG subcutaneous injection is a recombinant human growth hormone used to treat growth hormone deficiency.

hMG subcutaneous injection is a recombinant human growth hormone used to treat growth hormone deficiency. Used for Growth hormone deficiency in children.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namehMG subcutaneous injection
SponsorGranata Bio Corporation
Drug classGrowth hormone
TargetGrowth hormone receptor
ModalitySmall molecule
Therapeutic areaEndocrinology
PhasePhase 3

Mechanism of action

It works by replacing the body's natural growth hormone to stimulate growth and development in children with growth hormone deficiency. The exact mechanism of action is not fully understood, but it is believed to involve the stimulation of growth plates in bones and the regulation of growth hormone receptors.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about hMG subcutaneous injection

What is hMG subcutaneous injection?

hMG subcutaneous injection is a Growth hormone drug developed by Granata Bio Corporation, indicated for Growth hormone deficiency in children.

How does hMG subcutaneous injection work?

hMG subcutaneous injection is a recombinant human growth hormone used to treat growth hormone deficiency.

What is hMG subcutaneous injection used for?

hMG subcutaneous injection is indicated for Growth hormone deficiency in children.

Who makes hMG subcutaneous injection?

hMG subcutaneous injection is developed by Granata Bio Corporation (see full Granata Bio Corporation pipeline at /company/granata-bio-corporation).

What drug class is hMG subcutaneous injection in?

hMG subcutaneous injection belongs to the Growth hormone class. See all Growth hormone drugs at /class/growth-hormone.

What development phase is hMG subcutaneous injection in?

hMG subcutaneous injection is in Phase 3.

What are the side effects of hMG subcutaneous injection?

Common side effects of hMG subcutaneous injection include Injection site reaction, Gallstones, Diabetes mellitus, Scoliosis, Headache, Nausea.

What does hMG subcutaneous injection target?

hMG subcutaneous injection targets Growth hormone receptor and is a Growth hormone.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing